Ahmed Abuzaanona1, David Lanfear2. 1. Department of Internal Medicine, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI, 48202, USA. 2. Heart and Vascular Institute, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI, 48202, USA. dlanfea1@hfhs.org.
Abstract
PURPOSE OF REVIEW: Heart failure (HF) continues to be a public health burden despite advances in therapy, and the natriuretic peptide (NP) system is clearly of critical importance in this setting, spawning valuable diagnostic and prognostic testing, such as B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), as well as current and future therapeutics, including recombinant natriuretic peptides (e.g., carperitide, nesiritide) and recently sacubitril, which inhibits the key clearance mechanism for NPs. This article intends to summarize the existing evidence for the role of NP system genetic variation on cardiovascular phenotypes relevant to HF with particular focus on the potential impact on pharmacologic therapies. RECENT FINDINGS: Several genes in NP system have been interrogated, in many cases genetic variation impacting protein quantity and function or related disease states. Recent data supports genetic variants potentially impacting pharmacokinetics or dynamics of medications targeting the pathway. Growing evidence indicates the importance of genetic variation to the functioning of the NP system and its pharmacologic manipulation.
PURPOSE OF REVIEW: Heart failure (HF) continues to be a public health burden despite advances in therapy, and the natriuretic peptide (NP) system is clearly of critical importance in this setting, spawning valuable diagnostic and prognostic testing, such as B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), as well as current and future therapeutics, including recombinant natriuretic peptides (e.g., carperitide, nesiritide) and recently sacubitril, which inhibits the key clearance mechanism for NPs. This article intends to summarize the existing evidence for the role of NP system genetic variation on cardiovascular phenotypes relevant to HF with particular focus on the potential impact on pharmacologic therapies. RECENT FINDINGS: Several genes in NP system have been interrogated, in many cases genetic variation impacting protein quantity and function or related disease states. Recent data supports genetic variants potentially impacting pharmacokinetics or dynamics of medications targeting the pathway. Growing evidence indicates the importance of genetic variation to the functioning of the NP system and its pharmacologic manipulation.
Authors: Joshua W Knowles; Laurie M Erickson; Vanessa K Guy; Carlie S Sigel; Jennifer C Wilder; Nobuyo Maeda Journal: Hum Genet Date: 2002-10-10 Impact factor: 4.132
Authors: D Rehemudula; T Nakayama; M Soma; Y Takahashi; J Uwabo; M Sato; Y Izumi; K Kanmatsuse; Y Ozawa Journal: Circ Res Date: 1999-03-19 Impact factor: 17.367
Authors: N Matsukawa; W J Grzesik; N Takahashi; K N Pandey; S Pang; M Yamauchi; O Smithies Journal: Proc Natl Acad Sci U S A Date: 1999-06-22 Impact factor: 11.205
Authors: Hélène Choquet; Christine Cavalcanti-Proença; Cécile Lecoeur; Christian Dina; Stéphane Cauchi; Martine Vaxillaire; Samy Hadjadj; Fritz Horber; Natasha Potoczna; Guillaume Charpentier; Juan Ruiz; Serge Hercberg; Suliya Maimaitiming; Ronan Roussel; Michael Boenhnke; Anne U Jackson; Wolfgang Patsch; Franz Krempler; Benjamin F Voight; David Altshuler; Leif Groop; Gudmar Thorleifsson; Valgerdur Steinthorsdottir; Kari Stefansson; Beverley Balkau; Philippe Froguel; David Meyre Journal: Hum Mol Genet Date: 2009-04-18 Impact factor: 6.150
Authors: Chris P Gale; John E S White; Alan Hunter; Jane Owen; Jane Allen; Josie Watson; Ian Holbrook; Nigel P Durham; Maurice P Pye Journal: J Cardiovasc Med (Hagerstown) Date: 2011-09 Impact factor: 2.160